CYP3A pharmacogenetic association with tacrolimus pharmacokinetics differs based on route of drug administration.

Abstract excerpt

Tacrolimus is prescribed to the majority of transplant recipients to prevent graft rejection, and although patients are maintained on oral administration, nonoral routes of administration are frequently used in the initial post-transplant period. CYP3A5 genotype is an established predictor of oral tacrolimus dose requirements, and clinical guideline recommendations exist for CYP3A5-guided dose selection. However,...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Administration, Oral
• Share to Cytochrome P-450 CYP3A
• Share to Genotype